Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

UNCYBullishCorporate Developmentsnews

Medium materiality6/10

FDA Accepts UNCY NDA Resubmission for OLC with Six-Month Review

Oct 21, 2026, 7:12 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory progress typically adds upside potential, especially when a clear PDUFA timeline is set; prior CRL and new six-month review create both optimism and a defined near-term catalyst, though final approval remains uncertain.

AI summary

What happened, with direct paths to the underlying reporting

Unicycive Therapeutics disclosed that the FDA has accepted the NDA resubmission for oxylanthanum carbonate (OLC) after a June 2026 CRL. The agency classified the submission as Class II with a six-month review and a PDUFA target date of March 25, 2027. Approval could broaden phosphate-control options for CKD patients on dialysis and unlock potential value for UNCY, contingent on future safety and efficacy data.

FDA accepted UNCY's NDA resubmission for oxylanthanum carbonate (OLC).
NDA is Class II with a six-month review period by FDA.
PDUFA target action date set for March 25, 2027.
CRL issued in June 2026 preceded the resubmission.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

FDA Accepts UNCY NDA Resubmission for OLC with Six-Month Review

Unicycive Therapeutics Faces Class-Action Over FDA CRL Tied to Vendor Manufacturing